SEB Equities analyst Christopher Udhe downgraded Calliditas Therapeutics to Hold from Buy with a SEK 208 price target after Asahi Kasei announced an agreement to acquire Calliditas for about $39 per ADS or about $1.1B.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Wynn Resorts upgraded, PayPal initiated: Wall Street’s top analyst calls
- Calliditas Therapeutics downgraded to Neutral from Buy at Citi
- CHMP Endorses Calliditas’ Kinpeygo for IgAN
- Calliditas Therapeutics downgraded to Hold from Buy at Jefferies
- Calliditas Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue